China Genotyping Assay Market (2024-2029)
The China Genotyping Assay Market was valued at $724.5 Million in 2024 and projected to reach to $1647.7 Million by 2029, representing a compound annual growth rate of CAGR 17.9%. China's genotyping assay market is poised for exceptional growth through 2029, driven by government-backed precision medicine initiatives and substantial investments in genomic research infrastructure.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
China Genotyping Assay Market Trends and Insights
- This represents a compound annual growth rate of 17.9%, significantly outpacing global market growth.
- China's rapid advancement in genomic research, coupled with increasing government investment in precision medicine initiatives, is driving substantial demand for genotyping assays across clinical diagnostics, pharmaceutical development, and agricultural applications. The market growth in China is fueled by rising healthcare expenditure, expanding laboratory infrastructure, and growing adoption of personalized medicine practices.
- China's large population base and increasing prevalence of genetic disorders create substantial opportunities for genotyping assay providers.
- Between 2024 and 2029, China is expected to consolidate its position as a key regional hub for genomic testing, supported by technological innovation and regulatory framework improvements that facilitate market entry and clinical adoption..
Key Market Statistics
- CAGR (2024-2029) CAGR 17.9%
- Market Size, 2024 ~USD 724.5 Million
- Forecast, 2029 ~USD 1647.7 Million
- Country China
China Genotyping Assay Market Overview
Exceptional Growth Trajectory :
China's genotyping assay market is expanding at 17.9% CAGR, nearly 30% faster than the global average of 13.8%, reflecting strong domestic demand and accelerating adoption across healthcare institutions.
Government-Backed Precision Medicine :
Substantial government investment in precision medicine initiatives and genomic research infrastructure is catalyzing market expansion, positioning China as a leading hub for genotyping technology development and deployment.
Rapid Market Valuation Growth :
The market is projected to more than double from USD 724.5 million in 2024 to USD 1,647.7 million by 2029, demonstrating China's commitment to advancing personalized healthcare and genetic diagnostics.
Genomic Research Advancement :
China's rapid advancement in genomic research capabilities, combined with increasing healthcare spending and population awareness, is driving substantial demand for genotyping assays across clinical and research settings.
China Genotyping Assay Market Dynamics
- The country's healthcare modernization agenda prioritizes personalized medicine, creating robust demand for advanced genotyping technologies across hospitals, diagnostic centers, and research institutions. The market's 17.9% CAGR significantly outpaces global growth, reflecting China's strategic focus on genetic diagnostics and precision healthcare.
- Increasing healthcare expenditure, rising disease prevalence, and growing adoption of genomic testing in clinical practice will continue to fuel expansion, positioning China as a critical growth engine in the global genotyping assay market..
Market Ecosystem
GENOTYPING ASSAY MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
 |
Provides genotyping technologies, including TaqMan SNP Genotyping Assays and Applied Biosystems real-time PCR platforms, for detecting genetic variations in research, pharmacogenomics, and clinical applications | Enables accurate detection of genetic variants, supports high-throughput genotyping workflows, and facilitates applications in drug discovery, genetic research, and personalized medicine |
 |
Provides microarray-based genotyping solutions, including Infinium arrays, and sequencing technologies for genome-wide association studies, population genomics, and genetic variation analysis | Supports high-throughput genetic analysis, enables large-scale population studies, and facilitates research into disease susceptibility, pharmacogenomics, and precision medicine |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
Related Ecosystem
Advanced Genetic Sequencing
- Polymerase Chain Reaction (PCR)
- Reagents
- Assay Kits
- Bioinformatics
- Flow Cytometry
- Thermo Fisher Scientific Inc.
- Illumina, Inc.
- Qiagen N.V.
- Agilent Technologies, Inc.
- Danaher Corporation
Key Takeaways
- China's genotyping assay market is valued at USD 724.5 million in 2024 and is forecast to grow to USD 1,647.7 million by 2029, representing a 17.9% CAGR.
- China's market growth significantly exceeds the global CAGR of 13.8%, driven by government precision medicine initiatives and expanding healthcare infrastructure.
- China's large population and rising genetic disorder prevalence create substantial demand for genotyping assays across clinical, pharmaceutical, and agricultural sectors.
- China's regulatory improvements and technological innovation are positioning the country as a key regional hub for genomic testing and personalized medicine adoption.
Genotyping Assay Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2024 |
| Fastest Growing Segment | PHARMACOGENOMICS (Application) |
| Forecast Period | 2024–2029 |
| Growth Rate | CAGR of 13.8% from 2024 to 2029 |
| Largest Segment | REAGENTS & KITS (Product & Service) |
| Market Size Base Year (Billions) | ~USD 19.44 (2024) |
| Revenue Forecast (Billions) | ~USD 37.1 (2029) |
| Segments Covered | Product & Service, Type, Technology, Application, End User |
China Genotyping Assay Market Report Segmentation
5 segment dimensions are covered across the global market.
By Product & Service
- Bioinformatics
- Genotyping Services
- Instruments
- Reagents & Kits
By Type
- Amplified Fragment Length Polymorphism
- Analyzers
- Digital Polymerase Chain Reaction
- Next-Generation Sequencing
- Pyrosequencing
- Real-Time Polymerase Chain Reaction
- Restriction Fragment Length Polymorphism
- Sanger Sequencing
- Sequencers & Amplifiers
- Services
- Single-Strand Confirmation Polymorphism
- Software
By Technology
- Capillary Electrophoresis
- Matrix-Assisted Laser Desorption/Ionization-Time Of Flight Mass Spectrometry
- Microarrays
- Other Technologies
- Polymerase Chain Reaction
- Sequencing
By Application
- Agricultural Biotechnology
- Animal Genetics
- Diagnostics & Personalized Medicines
- Other Applications
- Pharmacogenomics
By End User
- Academic & Research Institutes
- Diagnostic Laboratories
- Other End Users
- Pharmaceutical & Biopharmaceutical Companies
CHINA: GENOTYPING ASSAY MARKET, BY END USER, 2022–2029
| Segment | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| ACADEMIC & RESEARCH INSTITUTES | 223.1 | 322 | 368.2 | 423.7 | 490.7 | 571.7 | 670.2 | 790.6 | 16.5 |
| DIAGNOSTIC LABORATORIES | 267.2 | 305.6 | 352 | 408 | 475.9 | 558.5 | 659.5 | 783.4 | 17.3 |
| OTHER END USERS | 262.2 | 227.7 | 258.6 | 295.7 | 340.1 | 393.7 | 458.5 | 537.2 | 15.7 |
| PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES | 320.7 | 371.2 | 432.5 | 506.8 | 597.5 | 708.5 | 845.1 | 1014 | 18.6 |
| TOTAL | 1073.2 | 1226.5 | 1411.3 | 1634.3 | 1904.2 | 2232.4 | 2633.3 | 3125.1 | 17.2 |
Target Audience
- In Vitro Diagnostics (IVD) Manufacturers : Need China-specific market data to assess market opportunity, plan product localization, and develop competitive strategies for genotyping assay portfolios in the world's fastest-growing genomic diagnostics market.
- Healthcare Investment & Private Equity Firms : Require validated market sizing and growth projections for China to evaluate investment opportunities in genomic diagnostics companies, precision medicine platforms, and healthcare technology ventures.
- Pharmaceutical & Biotech Companies : Need China market intelligence to support companion diagnostic development, precision medicine drug strategies, and partnerships with local diagnostic providers in this high-growth genomic testing market.
- Hospital & Diagnostic Laboratory Networks : Seek market outlook data to justify capital investments in genotyping infrastructure, plan service expansion, and benchmark competitive positioning within China's rapidly evolving precision medicine ecosystem.
- Government & Healthcare Policy Makers : Require comprehensive market analysis to inform precision medicine policy development, healthcare infrastructure planning, and resource allocation for genomic research initiatives across Chinese healthcare systems.
Key Companies in the China Genotyping Assay Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| SEQUENOM,INC. | United States | Private Company | MaterniT21 PLUS and VisibiliT NIPT,MaterniT21 GENOME and microarray (NextView),HerediT carrier screening (CF, Ashkenazi, SMA, fragile X), |
| DECODE GENETICS | Iceland | Private Company | Target discovery and validation for Amgen pipeline,Large-scale genome sequencing and analytics services,Data access, licensing, and collaborative research programs, |
| TRANSGENOMIC, INC. | United States | Public Company | Oncology and pharmacogenomics clinical trial services,Clinical oncology testing services (patient diagnostics and monitoring),Multiplexed ICE COLD-PCR reagents and technology licensing, |
| IMMUCOR, INC. | United States | Private Company | Transfusion serology reagents (manual and Capture),Automated serology instruments (NEO, Echo, Capture Workstation),Transplant & molecular assays (HEA/HPA typing, Array Imaging System, BASIS), |
| GENERAL ELECTRIC | United States | Public Company | Commercial Engines OE,Commercial Engines Services & MRO,Defense & Propulsion Technologies – Engines, |
| THERMO FISHER SCIENTIFIC INC. | United States | Public Company | Life Sciences Solutions,Analytical Instruments,Specialty Diagnostics, |
| ILLUMINA, INC. | United States | Public Company | Sequencing consumables (reagents, flow cells, library prep),Sequencing instruments,Array-based instruments and consumables, |
| DANAHER CORPORATION | United States | Public Company | Biotechnology,Life Sciences,Diagnostics, |
| QIAGEN | Netherlands | Public Company | Sample technology consumables and instruments,Molecular diagnostics assays (TB, oncology, sexual and reproductive health),PCR and enzymes (qPCR, dPCR, research PCR kits), |
| EUROFINS SCIENTIFIC | Luxembourg | Public Company | Food and Feed Testing,Environment Testing,Biopharma and Clinical Diagnostics, |
| AGILENT TECHNOLOGIES, INC. | United States | Public Company | Life Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets, |
| BIO-RAD LABORATORIES, INC. | United States | Public Company | Clinical Diagnostics,Life Science Research Tools,Other / Services and Software, |
| MERCK KGAA | Germany | Public Company | Life Science (lab reagents, consumables, bioprocessing, CDMO/testing),Healthcare (oncology, neurology, immunology, fertility, rare diseases),Electronics (semiconductor materials, specialty gases, display and OLED materials), |
| STANDARD BIOTOOLS | United States | Public Company | Proteomics platforms and consumables (SomaScan, CyTOF, Hyperion),Genomics and qPCR systems (Biomark X9 and related assays),Services, software, and other consumables, |
| REVVITY | United States | Public Company | Diagnostics instruments and automation (AutoDELFIA, GSP, EUROIMMUN, IDS-iSYS, EUROLabWorkstation),Diagnostics reagents, assays, and kits (prenatal, newborn, autoimmune, infectious disease, T-SPOT),Life science reagents and consumables (BioLegend, Dharmacon, NEXTFLEX, AlphaLISA portfolio), |
| PACBIO | United States | Public Company | Long-read instruments (Revio, Sequel, Vega),Long-read consumables (SMRT cells, library prep, binding and sequencing kits),Short-read instruments and consumables (Onso platform), |
| OXFORD NANOPORE TECHNOLOGIES PLC | United Kingdom | Public Company | PromethION platforms and consumables,MinION and portable platforms,GridION and mid-throughput systems, |
SEQUENOM,INC.
Sequenom, Inc. is a private molecular diagnostics company founded in 1994 in the United States with 434 employees. The company specializes in genetic testing and analysis.
DECODE GENETICS
Decode Genetics is a private genomics and biotechnology company founded in 1996 in Iceland with 331 employees. The company conducts genetic research and develops diagnostics based on genomic data.
TRANSGENOMIC, INC.
Transgenomic, Inc. is a public molecular diagnostics company founded in 1997 in the United States with 19 employees. The company develops genetic testing and analysis technologies.
IMMUCOR, INC.
Immucor, Inc. is a private blood bank and transfusion diagnostics company founded in 1982 in the United States with 1,125 employees. The company provides immunohematology and transfusion medicine solutions.
GENERAL ELECTRIC
General Electric is a public multinational conglomerate founded in 1892 in the United States with 57,000 employees. The company operates across diverse industries including healthcare, energy, and industrial sectors.
THERMO FISHER SCIENTIFIC INC.
Thermo Fisher Scientific Inc. is a public life sciences and diagnostics company founded in 1956 in the United States with 125,000 employees. The company provides laboratory equipment, reagents, and analytical instruments globally.
ILLUMINA, INC.
Illumina, Inc. is a public genomics and sequencing company founded in 1998 in the United States with 8,625 employees. The company develops DNA sequencing and genetic analysis technologies.
DANAHER CORPORATION
Danaher Corporation is a public diversified conglomerate founded in 1969 in the United States with 59,000 employees. The company operates across life sciences, diagnostics, and environmental solutions.
QIAGEN
Qiagen is a public molecular diagnostics and life sciences company founded in 1984 in the Netherlands with 5,500 employees. The company provides sample preparation, assay, and sequencing technologies.
EUROFINS SCIENTIFIC
Eurofins Scientific is a public laboratory services and diagnostics company founded in 1987 in Luxembourg with 65,694 employees. The company operates a global network of laboratories providing testing and analysis services.
AGILENT TECHNOLOGIES, INC.
Agilent Technologies, Inc. is a public life sciences and diagnostics company founded in 1999 in the United States with 18,000 employees. The company manufactures analytical instruments and laboratory equipment.
BIO-RAD LABORATORIES, INC.
Bio-Rad Laboratories, Inc. is a public life sciences and diagnostics company founded in 1952 in the United States with 7,450 employees. The company develops and manufactures clinical diagnostics and life science research products.
MERCK KGAA
Merck KGaA is a public pharmaceutical and life sciences company founded in 1668 in Germany with 59,077 employees. The company provides pharmaceuticals, chemicals, and laboratory solutions globally.
STANDARD BIOTOOLS
Standard Biotools is a public life sciences instrumentation company founded in 1999 in the United States with 387 employees. The company develops microfluidics and single-cell analysis technologies.
REVVITY
Revvity is a public life sciences and diagnostics company founded in 1937 in the United States with 11,000 employees. The company provides analytical instruments, reagents, and software solutions.
PACBIO
PacBio is a public genomics sequencing company founded in 2000 in the United States with 485 employees. The company develops long-read DNA sequencing technologies.
OXFORD NANOPORE TECHNOLOGIES PLC
Oxford Nanopore Technologies PLC is a public genomics sequencing company founded in 2005 in the United Kingdom with 1,316 employees. The company develops portable DNA and RNA sequencing technologies.
Reasons to Buy this Report
- Market Size & Growth Validation : Obtain precise market valuation data for China (USD 724.5M in 2024) with verified 17.9% CAGR projections through 2029, enabling accurate financial forecasting and investment decision-making for regional expansion strategies.
- Competitive Positioning Intelligence : Understand China's market dynamics relative to global trends (13.8% CAGR), identifying competitive advantages and market gaps specific to Chinese healthcare infrastructure and regulatory environment.
- Government Initiative Insights : Access detailed analysis of China's precision medicine investments and genomic research funding, helping stakeholders align product development and market entry strategies with government priorities and policy drivers.
- Demand Forecasting & Planning : Leverage comprehensive 5-year forecast data to project market demand, capacity requirements, and revenue potential across Chinese healthcare institutions, diagnostic centers, and research organizations.
- Strategic Market Entry Framework : Develop informed go-to-market strategies for China with localized insights on adoption rates, healthcare spending patterns, and institutional preferences specific to the genotyping assay sector.
Frequently asked questions
What is the current size of China's genotyping assay market?
China's genotyping assay market was valued at USD 724.5 million in 2024 and is expected to grow to USD 1,647.7 million by 2029.
What is the projected growth rate for China's genotyping assay market?
China's genotyping assay market is projected to grow at a compound annual growth rate (CAGR) of 17.9% from 2024 to 2029.
How does China's market growth compare to global trends?
China's genotyping assay market CAGR of 17.9% significantly outpaces the global CAGR of 13.8%, reflecting stronger regional demand and investment.
What are the primary drivers of growth in China's genotyping assay market?
Key drivers include government precision medicine initiatives, rising healthcare expenditure, expanding laboratory infrastructure, and increasing adoption of personalized medicine practices in China.
Which sectors are driving demand for genotyping assays in China?
Demand in China is driven by clinical diagnostics, pharmaceutical development, agricultural applications, and personalized medicine initiatives across healthcare institutions.
RESEARCH METHODOLOGY
This study involved four major activities to estimate the current size of the genotyping assay market. Exhaustive secondary research was conducted to gather information on the market, its peer markets, and its parent market. These findings, assumptions, and sizing were then validated with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the total market size. Following this, data triangulation was used to estimate the market size of segments and subsegments.
Secondary Research
Secondary research was primarily used to identify and gather information for the extensive, technical, market-oriented, and commercial study. Secondary sources for this study included publications from government agencies, such as the National Center for Biotechnology Information (NCBI), National Institutes of Health (NIH), World Health Organization (WHO), Food and Drug Administration (FDA), European Medicines Agency (EMA), Pharmaceutical Research and Manufacturers of America (PhRMA), Global Cancer Observatory (GLOBOCAN), Centers for Disease Control and Prevention (CDC), and European Federation of Biotechnology. Secondary sources also included corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); business magazines and research journals; press releases; and trade, business, and professional associations. These sources were used to obtain key information on major players, global product revenues, market classification, segmentation by industry trends and regional/country-level markets, market developments, and technology perspectives. Secondary data were collected and analyzed to determine the overall size of the global genotyping assay market, and the findings were validated through primary research.
Primary Research
In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among others, to obtain and verify critical qualitative and quantitative information and to assess market prospects. Primary sources from both the supply and demand sides of the market were interviewed to gather qualitative and quantitative data. The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The global size of the genotyping assay market was estimated using multiple approaches. A detailed market estimation approach was used to estimate and validate the market value and other dependent submarkets. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
Genotyping Assay Market : Top-Down and Bottom-Up Approach
Data Triangulation
After estimating the overall market size through the market size estimation process, the total market was divided into several segments. To complete the overall market engineering process and arrive at the exact statistics for all segments, the data triangulation procedure was employed; it involved analyzing various factors and trends from both the demand and supply sides.
Market Definition
Genotyping assays are laboratory techniques that identify genetic variations in an individual's DNA. These assays detect single-nucleotide polymorphisms (SNPs), insertions, deletions, and other variants using technologies such as polymerase chain reaction (PCR), microarrays, and DNA sequencing. Genotyping assays are widely used in clinical diagnostics, personalized medicine, pharmacogenomics, drug discovery and development, and genetic research. They also have applications in agricultural biotechnology and animal genetics, supporting crop improvement, livestock breeding, and genetic trait identification. Increasing demand for precision medicine, advances in genomic technologies, and the growing use of genetic analysis in biomedical research are driving the adoption of genotyping assays across healthcare, pharmaceutical, biotechnology, and research industries.
Key Stakeholders
- Academic Research Institutes
- Raw Materials Manufacturers & Distributors
- Contract Research Organizations (CROs)
- Manufacturer Service Providers
- Market Research and Consulting Firms
- Pharmaceutical & Biotechnology Companies
- Regulatory Agencies
- Venture Capitalists
- Government organizations
- Private Research Firms
- Contract Development and Manufacturing Organizations (CDMOs)
Report Objectives
- To define, describe, and forecast the genotyping assays market by product & service, technology, application, end user, and region
- To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall lipid nanoparticles market
- To analyze opportunities for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to six regions: North America (US and Canada), Europe (Germany, France, the UK, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), Middle East and Africa
- To profile the key players and analyze their market share and core competencies
- To analyze competitive developments, such as product launches, partnerships, agreements, collaborations, and expansions
- To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy
Available customizations:
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:
Geographical Analysis
- Further breakdown of the Rest of genotyping assay market, by country
- Further breakdown of the Rest of Asia Pacific genotyping assay market, by country
Company Information
- Detailed analysis and profiling of additional market players (up to five)
Segment Analysis
-
Cross-segment analysis
Get the Full Genotyping Assay Market Report
Full forecast, segment splits, and company analysis for all Genotyping Assay Market.
- US Genotyping Assay Market
- Canada Genotyping Assay Market
- Germany Genotyping Assay Market
- UK Genotyping Assay Market
- France Genotyping Assay Market
- Italy Genotyping Assay Market
- Spain Genotyping Assay Market
- Japan Genotyping Assay Market
- India Genotyping Assay Market
- Brazil Genotyping Assay Market
- Mexico Genotyping Assay Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report
